Arrowhead Pharmaceuticals
Develops targeted RNAi medicines and markets REDEMPLO for familial chylomicronemia syndrome.
$84.80
After-hours close−0.11 (−0.13%)
At close$84.91(−4.15%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 93.36%131.50M sharesInsiders 3.59%5.06M sharesOther 3.05%4.29M shares
Shares outstanding 140.86M · Float 122.78M · 87.2% free float
Institutions13F, as of Jun 30, 2026
521 holders · 131.50M shares · 126 new positions · 281 increased · 161 reduced · 63 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.83M | 10.53% | −3.33M | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 11.36M | 8.06% | +655.6K | Aug 14, 2026 |
| FMR LLC | 8.04M | 5.71% | +773.2K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 6.35M | 4.51% | −794.8K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.11M | 4.34% | +78.5K | Aug 13, 2026 |
| State Street Corp | 5.69M | 4.04% | −801.5K | Aug 7, 2026 |
| Norges Bank | 3.90M | 2.77% | +3.90Mnew | Aug 12, 2026 |
| Invesco Ltd. | 3.88M | 2.76% | +603.3K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.20% | 17.10M | 13G | Apr 24, 2026 ↗ |
| Avoro Capital Advisors LLC | 8.30% | 11.52M | 13G | Aug 14, 2025 ↗ |
| FMR LLC | 5.20% | 7.35M | 13G | May 6, 2026 ↗ |
| Vanguard Portfolio Management | 5.19% | 7.27M | 13G | Apr 28, 2026 ↗ |
| State Street Corporation | 5.10% | 6.35M | Oct 16, 2024 ↗ | |
| Vanguard Capital Management | 5.05% | 7.08M | 13G | Apr 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Christopher Richard Anzalone | director, officer: Chief Executive Officer | 3.79M | 2.69% | Jan 5, 2026 |
| Patrick O'Brien | officer: COO | 472.8K | 0.34% | Jan 8, 2026 |
| James C. Hamilton | officer: Chief Medical Officer | 227.0K | 0.16% | Apr 24, 2026 |
| Daniel Joseph Apel | officer: Chief Financial Officer | 162.9K | 0.12% | Apr 24, 2026 |
| Michael S. Perry | director | 111.5K | 0.08% | Aug 20, 2026 |
| Mauro Ferrari | director | 69.1K | 0.05% | Dec 30, 2025 |
| Hongbo Lu | director | 57.7K | 0.04% | May 14, 2026 |
| William D. Waddill | director | 56.6K | 0.04% | Dec 23, 2025 |
| Douglas S. Ingram | director | 46.2K | 0.03% | Dec 18, 2025 |
| Victoria Vakiener | director | 35.7K | 0.03% | Dec 23, 2025 |
2 ten-percent owners hold 279.4K shares by Form 4, outside the officers-and-directors figure above · 15 people have not refiled in the last 18 months (2.48M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Adeoye Y. Olukotundirector | Sale | 2,000 | $86.96 | 31,600 |
| Aug 18, 2026 | Michael S. Perrydirector | Sale | 11,600 | $87.30 | 111,459 |
| May 12, 2026 | Hongbo Ludirector | Sale | 2,970 | $76.88 | 52,012 |
| Apr 23, 2026 | James C. Hamiltonofficer: Chief Medical Officer | Sale | 10,000 | $75.00 | 226,958 |
| Apr 22, 2026 | Daniel Joseph Apelofficer: Chief Financial Officer | Sale · 3 lots | 13,095 | $71.35 | 162,905 |
| Mar 5, 2026 | James C. Hamiltonofficer: Chief Medical Officer | Sale | 10,000 | $64.19 | 236,958 |
| Jan 2, 2026 | Christopher Richard Anzalonedirector, officer: Chief Executive Officer | Sale · 2 lots | 13,187 | $66.10 | 3,792,739 |
| Jan 5, 2026 | James C. Hamiltonofficer: Chief Medical Officer | Sale · 7 lots | 40,164 | $63.11 | 171,958 |
| Jan 5, 2026 | Patrick O'Brienofficer: COO | Sale · 12 lots | 49,493 | $63.11 | 474,908 |
| Dec 26, 2025 | Mauro Ferraridirector | Sale | 7,530 | $70.00 | 69,053 |
CongressHouse and Senate disclosures
Not reported.